CLK3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL513882	0.46	15/20
SCHEMBL513237	0.60	9/20
Benzo[D]Thiazole (SCHEMBL544175)	0.34	7/20
SCHEMBL81513	0.56	5/20
SCHEMBL81160	0.50	5/20
SCHEMBL142464	0.49	4/20
SCHEMBL473752	0.49	4/20
SCHEMBL497022	0.74	3/20
SCHEMBL497023	0.74	3/20
SCHEMBL82928	0.69	3/20
SCHEMBL473761	0.57	3/20
SCHEMBL173292	0.52	3/20
SCHEMBL182389	0.51	3/20
SCHEMBL183411	0.51	3/20
SCHEMBL473697	0.49	3/20
SCHEMBL560217	0.46	3/20
SCHEMBL82789	0.46	3/20
SCHEMBL176241	0.45	3/20
SCHEMBL558738	0.43	3/20
SCHEMBL10459	0.40	3/20

Clinical trials — most relevant to CLK3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cardiac REperfusion With Intralipid® at Reperfusion	PHASE2/PHASE3	UNKNOWN
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer	PHASE2	COMPLETED
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations	PHASE2	RECRUITING
Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement	PHASE2	UNKNOWN
Biological Effects of Quercetin in COPD Phase II	PHASE2	UNKNOWN
Biological Effects of Quercetin in COPD	PHASE1/PHASE2	UNKNOWN
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2	PHASE1	COMPLETED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	PHASE1	COMPLETED
A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Investigations of Juvenile Neuronal Ceroid Lipofuscinosis	nan	RECRUITING
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
Genetic Analysis of Craniosynostosis, Philadelphia Type	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Genomic Analysis of Families With a History of Discordant Cancers	nan	RECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Data Collection, Clinical Care and Interventions in CCR, NCI	nan	ENROLLING_BY_INVITATION
LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers	nan	COMPLETED
A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib	nan	COMPLETED
Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate	nan	RECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Strategy for Management of Patients With Hereditary Cancer Syndromes (HCS) in a Rural Environment	nan	ENROLLING_BY_INVITATION
The Effect of Blueberries on Enhancing Insulin Sensitivity in Humans: A Pilot Study	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a CLK3 binder may also engage these)

Protein	Name	Similarity
Q63117	—	1.000	Q63117 →
Q3SX21	—	1.000	Q3SX21 →
O35492	—	1.000	O35492 →
CLK4	Dual specificity protein kinase CLK4	1.000	landscape →
P22518	—	1.000	P22518 →
CLK1	Dual specificity protein kinase CLK1	0.998	landscape →
O35491	—	0.997	O35491 →
O35493	—	0.993	O35493 →
CLK2	Dual specificity protein kinase CLK2	0.991	landscape →
Q53N72	—	0.983	Q53N72 →
Q9LV37	—	0.983	Q9LV37 →
Q4WYR6	—	0.983	Q4WYR6 →
O35832	—	0.983	O35832 →
Q0E459	—	0.982	Q0E459 →
Q5BAE1	—	0.982	Q5BAE1 →
A2X0M1	—	0.982	A2X0M1 →
Q4FCZ5	—	0.982	Q4FCZ5 →
Q5VP69	—	0.981	Q5VP69 →
Q9FGW5	—	0.981	Q9FGW5 →
C0RW22	—	0.981	C0RW22 →
Q5SN53	—	0.981	Q5SN53 →
Q84M93	—	0.980	Q84M93 →
Q75KK8	—	0.980	Q75KK8 →
O35831	—	0.980	O35831 →
Q8W4J2	—	0.980	Q8W4J2 →
O23145	—	0.980	O23145 →
Q23357	—	0.980	Q23357 →
Q04899	—	0.980	Q04899 →
P43289	—	0.980	P43289 →
B0VXL7	—	0.979	B0VXL7 →